Genomatix Wins BioChance Grant for $1.6 Mio Research Project into RNAi Mediated Regulatory Networks

18-Sep-2006

Genomatix Software GmbH has won a "BioChance" research contract from the German Federal Ministry of education and Research to pursue research in RNAi mediated regulatory networks and to further expand its competence and product line into this exciting new field. The project is scheduled to run for two years and is worth more than US$ 1.6 million.

Genomatix own unique competence in the biology of gene regulation will be complemented by at least two academic research partners (the LMU Munich and the DKFZ Heidelberg) who will carry out the wet lab experimental part of the research.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Mayo Clinic researchers discover drug can prevent colon cancer development in mice

Merck Announces Elevian as Winner of its North American Advance Biotech Grant - Recombinant protein has the potential to accelerate ischemic and hemorrhagic stroke recovery

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

American Peptide Company Announces Expansion of Its GMP Manufacturing Facility - Company expands capacity to accommodate large scale peptide production for growing customer base

New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel - Capricorn Venture Partners leads 1st financing round of € 3 million

Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Former Becton Dickinson and Wyeth Executive Joins Merck

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

Voyager Therapeutics & Genzyme collaborate to develop and commercialize novel AAV gene therapies for patients with CNS Disorders

Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset

Vertex Pharmaceuticals: Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor

Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea